ANDREW YEE to Monoclonal Gammopathy of Undetermined Significance
This is a "connection" page, showing publications ANDREW YEE has written about Monoclonal Gammopathy of Undetermined Significance.
Connection Strength
0.471
-
Daratumumab in high-risk MGUS and low-risk smoldering myeloma: results of the Phase II D-PRISM study. Nat Commun. 2026 Apr 08; 17(1).
Score: 0.242
-
Psychosocial and NF-?B Activity Effects of the Stress Management and Resiliency Training: Relaxation Response Resiliency Program (SMART-3RP) on Patients With MGUS and Smoldering Multiple Myeloma: A Randomized Waitlist Control Trial. Psychooncology. 2025 Jul; 34(7):e70216.
Score: 0.229